Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

Mario Cazzola, Yves Beguin, Janusz Kloczko, Ivan Spicka, Bertrand Coiffier

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30 000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10 000 t.i.w. administration in anaemic patients with lymphoprolfferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values ≤100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90% confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72% vs 75%, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective.

Original languageEnglish
Pages (from-to)386-393
Number of pages8
JournalBritish Journal of Haematology
Volume122
Issue number3
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Erythropoietin
Neoplasms
Lymphoproliferative Disorders
Non-Hodgkin's Lymphoma
Anemia
Serum
B-Cell Chronic Lymphocytic Leukemia
epoetin beta
Multiple Myeloma
Hemoglobins
Confidence Intervals
Therapeutics

Keywords

  • Anaemia
  • Chronic lymphocytic leukaemia
  • Erythropoietin
  • Multiple myeloma
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. / Cazzola, Mario; Beguin, Yves; Kloczko, Janusz; Spicka, Ivan; Coiffier, Bertrand.

In: British Journal of Haematology, Vol. 122, No. 3, 08.2003, p. 386-393.

Research output: Contribution to journalArticle

@article{6e5786779bb1476c9db1395b063984a7,
title = "Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production",
abstract = "Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30 000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10 000 t.i.w. administration in anaemic patients with lymphoprolfferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values ≤100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90{\%} confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72{\%} vs 75{\%}, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective.",
keywords = "Anaemia, Chronic lymphocytic leukaemia, Erythropoietin, Multiple myeloma, Non-Hodgkin's lymphoma",
author = "Mario Cazzola and Yves Beguin and Janusz Kloczko and Ivan Spicka and Bertrand Coiffier",
year = "2003",
month = "8",
doi = "10.1046/j.1365-2141.2003.04439.x",
language = "English",
volume = "122",
pages = "386--393",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "3",

}

TY - JOUR

T1 - Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production

AU - Cazzola, Mario

AU - Beguin, Yves

AU - Kloczko, Janusz

AU - Spicka, Ivan

AU - Coiffier, Bertrand

PY - 2003/8

Y1 - 2003/8

N2 - Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30 000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10 000 t.i.w. administration in anaemic patients with lymphoprolfferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values ≤100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90% confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72% vs 75%, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective.

AB - Epoetin beta, three-times weekly (t.i.w.), is effective in reversing anaemia in lymphoproliferative disorders. The current study investigated whether an epoetin beta dose of 30 000 IU given subcutaneously once weekly (q.w.) was at least as effective as 10 000 t.i.w. administration in anaemic patients with lymphoprolfferative malignancy and defective endogenous erythropoietin (Epo) production. Overall, 241 anaemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, all with serum Epo values ≤100 mU/ml, were randomized to receive the q.w. (n = 119) or t.i.w. (n = 122) regimen for 16 weeks. The primary efficacy criterion, i.e. the time-adjusted area under the haemoglobin-time curve from weeks 5-16, was comparable between the q.w. and t.i.w. groups [difference = - 0.20 g/dl (90% confidence interval - 0.52-0.11)]. Moreover, response rates were high and similar in both arms (72% vs 75%, q.w. and t.i.w. groups respectively). Baseline serum Epo was predictive of response: the lower serum Epo, the higher the likelihood of response (P = 0.002). Thus, epoetin beta administered q.w. is an effective and convenient treatment for anaemia in patients with lymphoproliferative disorders. Tailoring this treatment modality to subjects with defective endogenous Epo production represents a rational use of epoetin from both a medical and a community perspective.

KW - Anaemia

KW - Chronic lymphocytic leukaemia

KW - Erythropoietin

KW - Multiple myeloma

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0037719383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037719383&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04439.x

DO - 10.1046/j.1365-2141.2003.04439.x

M3 - Article

VL - 122

SP - 386

EP - 393

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -